Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Open Label Study of Long Term Safety Evaluation of Alirocumab

ClinicalTrials.gov ID: NCT01954394

Public ClinicalTrials.gov record NCT01954394. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 11:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Open-Label Extension Study of EFC12492, R727-CL-1112, EFC12732 and LTS11717 Studies to Assess the Long-Term Safety and Efficacy of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Primary Objective: To assess the long-term safety of alirocumab (SAR236553/REGN727) when added to lipid-lowering therapy in participants with heterozygous familial hypercholesterolemia (heFH) who had completed EFC12492 (NCT01623115), R727-CL-1112 (NCT01709500), EFC12732 (NCT01617655) and LTS11717 (NCT01507831). Secondary Objectives: * To evaluate the long-term efficacy of alirocumab on lipid parameters. * To evaluate the long-term immunogenicity of alirocumab.

Study identification

NCT ID
NCT01954394
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Sanofi
Industry
Enrollment
986 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 16, 2013
Primary completion
Jun 29, 2017
Completion
Jun 29, 2017
Last update posted
Jul 23, 2018

2013 – 2017

United States locations

U.S. sites
44
U.S. states
23
U.S. cities
42
Facility City State ZIP Site status
Investigational Site Number 840321 Huntsville Alabama 35801
Investigational Site Number 840341 Tempe Arizona 85282
Investigational Site Number 840334 Bell Gardens California 90201
Investigational Site Number 840319 Fountain Valley California 92708
Investigational Site Number 840336 Los Angeles California 90048
Investigational Site Number 840339 Mission Viejo California 92691
Investigational Site Number 840337 Newport Beach California 92663
Investigational Site Number 840306 Golden Colorado 80401
Investigational Site Number 840328 Washington D.C. District of Columbia 20037
Investigational Site Number 840344 Atlantis Florida 33462
Investigational Site Number 840353 Clearwater Florida 33756
Investigational Site Number 840318 Fort Lauderdale Florida 33308-4311
Investigational Site Number 840327 Jacksonville Florida 32216
Investigational Site Number 840309 Miami Florida 33174
Investigational Site Number 840351 Sarasota Florida 34239
Investigational Site Number 840315 Evanston Illinois 60201
Investigational Site Number 840305 Oakbrook Terrace Illinois 60181
Investigational Site Number 840333 Iowa City Iowa 52242
Investigational Site Number 840329 Kansas City Kansas 66160
Investigational Site Number 840345 Auburn Maine 04210
Investigational Site Number 840338 Biddeford Maine 04005
Investigational Site Number 840322 Boston Massachusetts 02114
Investigational Site Number 840346 Framingham Massachusetts 01702
Investigational Site Number 840317 St Louis Missouri 63110
Investigational Site Number 840349 St Louis Missouri 63136
Investigational Site Number 840314 Morristown New Jersey 07901
Investigational Site Number 840316 New York New York 10032
Investigational Site Number 840324 Poughkeepsie New York 12601
Investigational Site Number 840303 Charlotte North Carolina 28204
Investigational Site Number 840320 Durham North Carolina 27710
Investigational Site Number 840348 Raleigh North Carolina 27609
Investigational Site Number 840340 Cincinnati Ohio 45227
Investigational Site Number 840302 Marion Ohio 43302
Investigational Site Number 840330 Portland Oregon 97239
Investigational Site Number 840352 Beaver Pennsylvania 15009
Investigational Site Number 840308 Philadelphia Pennsylvania 19104
Investigational Site Number 840342 Scranton Pennsylvania 18503
Investigational Site Number 840304 Summerville South Carolina 29485
Investigational Site Number 840311 Dallas Texas 75216
Investigational Site Number 840312 Dallas Texas 75226
Investigational Site Number 840301 Fort Worth Texas 76104
Investigational Site Number 840343 Bountiful Utah 84010
Investigational Site Number 840354 Chesapeake Virginia 23320
Investigational Site Number 840350 Spokane Washington 99204

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 133 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01954394, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 23, 2018 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01954394 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →